← Back to Clinical Trials
Recruiting NCT04806568

NCT04806568 MS-NEUROPLAST: Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients with Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04806568
Status Recruiting
Phase
Sponsor Aristotle University Of Thessaloniki
Condition Multiple Sclerosis
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2020-12-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Cognitive TrainingMonitoring of daily activity

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2020-12-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical study aims to identify MS related beneficial plasticity and by contrast maladaptive reorganization in combination with elements of daily functional status as a response to a cognitive training program

Eligibility Criteria

Inclusion Criteria for people with MS: * Male/female patients aged 18 to 65 years at screening * Diagnosis of MS according to the 2017 Revised McDonald criteria * Disability status at screening with an EDSS score of 0 to 6.5 * Relapsing MS and progressive MS as defined by Lublin * Neurologically stable within 1 month prior to screening * Patients receiving the same Disease Modifying Treatment (DMT) for at least 6 months Exclusion Criteria for people with MS: * Patients suspected of not being able or willing to cooperate or comply with study protocol requirements * Patients meeting criteria for other demyelinating diseases of the CNS * Patients with active chronic disease (or stable but treated with immune therapy) of the immune system other than MS * Patients with any other significant CNS disease or serious psychiatric disorder which can interfere with the patient's ability to cooperate or comply with the study procedure * Patients unable or unwilling to undergo MRI scans and EEG Inclusion Criteria for Healthy Controls: • Normal hearing and normal or corrected-to-normal vision Exclusion Criteria for Healthy Controls: * Any diagnosed neurological, mental, developmental, or psychiatric disorder * Unrecovered neurological disorders (i.e., stroke, traumatic brain injury) * Unstable medication within the last 3 months * Intake of central nervous drugs (e.g., antidepressants) * Severe physical disorder * Concurrent participation in another relevant study * Patients unable or unwilling to undergo EEG measurements

Contact & Investigator

Central Contact

Charis Styliadis, PhD

✉ styliadis@hotmail.com

📞 6942618582

Principal Investigator

Charis Styliadis, PhD

PRINCIPAL INVESTIGATOR

Aristotle University Of Thessaloniki

Frequently Asked Questions

Who can join the NCT04806568 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04806568 currently recruiting?

Yes, NCT04806568 is actively recruiting participants. Contact the research team at styliadis@hotmail.com for enrollment information.

Where is the NCT04806568 trial being conducted?

This trial is being conducted at Thessaloniki, Greece.

Who is sponsoring the NCT04806568 clinical trial?

NCT04806568 is sponsored by Aristotle University Of Thessaloniki. The principal investigator is Charis Styliadis, PhD at Aristotle University Of Thessaloniki. The trial plans to enroll 180 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology